Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in comparison with imatinib, for the very first-line treatment method of CML-CP. 5 hundred and nineteen people with freshly diagnosed CML-CP were randomly assigned to receive dasatinib in a dose of 100 mg when day-to-day (259 sufferers) or https://lukasnamzk.luwebs.com/29313521/little-known-facts-about-azd0156